|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
Picking up on the thread of my last editorial in the Summer issue of PMPS, it's painful to hear of the widespread shake-out going on throughout our industry. It seems that no organisation is so big that it can't get bigger through consolidation, without shedding layers of management or teams of skilled professionals, while none is so small that it lacks scope for becoming even leaner by downsizing. In the current climate of economic downturn, the bottom line is that accounts matter a great deal for the survival of businesses as the struggle continues to prune costs and aim for profitability.
Browsing the bumper crop of articles in the current and recent issues of PMPS, it appears that intellectual property (IP) has moved centre stage from the periphery of the
life science arena. In one corner are illegal counterfeiting practices, out to make a fast buck from pushing pirated versions of drugs by exploiting an unfulfilled consumer-driven demand (see page 109). In another there's a rising tide of products losing their patent protection and opening the way for cheaper generic versions, meeting the need for governments to contain costs (see page88). This leaves big pharma with the enormous task of replenishing its depleted development pipeline with innovative products from the biotech sector, while remaining saddled with the mounting costs of development. Overseeing this turf war is the regulatory gamekeeper barely able to keep up with the game (see page 72 on EU Clinical Trials Directive).
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Signant Health Launches Partner Program to Team with Clinical Research Organizations (CROs) Committed to Improving Clinical Trials with Patient-Centric Technology
PHILADELPHIA – August 12, 2019: Signant Health (signanthealth.com), a leading provider of technology for clinical research, today launches the Signant Health Partner Program, a significant investment the company is making to enable clinical research organizations (CROs) to better serve sponsors in the areas of Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions. By becoming a Signant Partner, CROs will benefit from new commercial and operational advantages that only come with membership.
More info >> |
|
 |
White Papers |
 |
|
Digital Transformation of the Cold Chain
Sensitech EMEA
The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >> |
|
 |
Industry Events |
 |
SAPHEX 2019
23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA
SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention
Centre, Johannesburg, South Africa.
More info >> |
|
|
